This inventor holds 2 USPTO granted patents. Top assignee: Ludwig Institute for Cancer Research Limited. Active years: 2009-2013.
Location History:
- Ellicott City, MD (US) (2009)
- Baltimore, MD (US) (2013)
Company Filing History:
Years Active: 2009-2013
Title: Innovations of Lan-Qing Huang in Cancer Research
Introduction
Lan-Qing Huang is a notable inventor based in Baltimore, MD (US), recognized for his contributions to cancer research. He holds two patents that focus on tumor rejection antigens, which are crucial for advancing cancer treatment.
Latest Patents
Huang's latest patents include "Tumour rejection antigens - Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1." This innovation aims to enhance the immune response against tumors. Another patent is titled "Tumor rejection antigens - Polypeptides comprising an unbroken sequence of amino acids from SEQ ID NO: 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1." Both patents reflect his commitment to improving cancer therapies.
Career Highlights
Lan-Qing Huang is affiliated with the Ludwig Institute for Cancer Research Limited, where he conducts significant research in the field of oncology. His work has contributed to a deeper understanding of how the immune system can be harnessed to fight cancer.
Collaborations
Some of his notable coworkers include Aline Van Pel and Francis Brasseur, who collaborate with him on various research projects. Their combined expertise enhances the research output and innovation in cancer treatment.
Conclusion
Lan-Qing Huang's innovative work in cancer research, particularly through his patents, showcases his dedication to advancing medical science. His contributions are vital in the ongoing fight against cancer, and his collaborations further strengthen the impact of his research.